Financial Statements

August 31, 2024 and 2023

(With Independent Auditor's Report Thereon)





Independent Auditor's Report

Board of Directors Alpha Omega Alpha Honor Medical Society

Opinion

We have audited the accompanying financial statements of Alpha Omega Alpha Honor Medical Society, which comprise the statements of financial position as of August 31, 2024 and 2023, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Alpha Omega Alpha Honor Medical Society as of August 31, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America (GAAP).

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Alpha Omega Alpha Honor Medical Society and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with GAAP and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Alpha Omega Alpha Honor Medical Society's ability to continue as a going concern for one year beyond the date the financial statements are available for issuance.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

Board of Directors Alpha Omega Alpha Honor Medical Society

In performing and audit in accordance with GAAS, we:

Kundinger, Corder & Montaga, P.C.

- Exercise professional judgement and maintain professional skepticism throughout the audit
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Alpha Omega Alpha Honor Medical Society's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Alpha Omega Alpha Honor Medical Society's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

February 21, 2025

Alpha Omega Alpha Honor Medical Society Statements of Financial Position August 31, 2024 and 2023

	2024	2023
Assets		
Cash and cash equivalents \$	846,853	710,163
Investments (note 3)	28,970,159	25,619,718
Prepaid expenses and other assets	10,537	35,706
Operating lease right-of-use asset (note 6)	95,330	184,138
Total assets \$	29,922,879	26,549,725
Liabilities and net assets		
Accounts payable and accrued expenses \$	210,548	171,624
Fellowships, grants, and awards payable (note 4)	403,781	388,496
Operating lease liability (note 6)	95,050	183,598
Deferred lifetime dues	10,168,499	9,961,124
Total liabilities	10,877,878	10,704,842
Net assets		
Without donor restrictions	18,907,802	15,718,443
With donor restrictions (note 5)	137,199	126,440
Total net assets	19,045,001	15,844,883
Commitment (note 7)		
Total liabilities and net assets \$	29,922,879	26,549,725

Alpha Omega Alpha Honor Medical Society Statement of Activities Year Ended August 31, 2024

		XX':1 . 1	XX7°.1 1	
		Without donor restrictions	With donor restrictions	Total
Operating revenue and support		Testrictions	<u>restrictions</u>	
Membership dues	\$	1,899,492	_	1,899,492
Insignia and other	Ψ	218,295	_	218,295
Contributions		214,249	_	214,249
Net assets released from restrictions (note 5)		4,500	(4,500)	
Total operating revenue and support		2,336,536	(4,500)	2,332,036
Operating expenses				
Program expenses				
The Pharos		654,155	_	654,155
Student awards		435,603	_	435,603
Leadership program		321,086	_	321,086
Chapter development and other		287,751	_	287,751
Visiting professorships		113,281	_	113,281
Insignia		233,536	_	233,536
Distinguished teacher awards		86,980	_	86,980
Professionalism awards		172,079		172,079
Total program expenses		2,304,471		2,304,471
Supporting services				
Management and general		486,683	_	486,683
Solicitations		77,760		77,760
Total supporting services		564,443		564,443
Total operating expenses		2,868,914		2,868,914
Change in net assets from operating activities		(532,378)	(4,500)	(536,878)
Nonoperating activities				
Investment return, net (note 3)		3,721,737	15,259	3,736,996
Change in net assets		3,189,359	10,759	3,200,118
Net assets, beginning of year		15,718,443	126,440	15,844,883
Net assets, end of year	\$	18,907,802	137,199	19,045,001

Alpha Omega Alpha Honor Medical Society Statement of Activities Year Ended August 31, 2023

		Without donor	With donor	T-4-1
On anoting navanus and sunnant		restrictions	restrictions	Total
Operating revenue and support Membership dues	\$	1 950 440		1 950 440
Insignia and other	Ф	1,859,449 112,481	_	1,859,449 112,481
Contributions		210,687	_	210,687
Net assets released from restrictions (note 5)		4,500	(4,500)	210,067
				2 250 617
Total operating revenue and support		2,264,117	(4,500)	2,259,617
Operating expenses				
Program expenses				
The Pharos		648,188	_	648,188
Student awards		402,439	_	402,439
Leadership program		317,321	_	317,321
Chapter development and other		209,706	_	209,706
Visiting professorships		136,133	_	136,133
Insignia		193,342	_	193,342
Distinguished teacher awards		94,171	_	94,171
Professionalism awards		137,934		137,934
Total program expenses		2,139,234		2,139,234
Supporting services				
Management and general		516,272	_	516,272
Solicitations		40,556	_	40,556
Total supporting services		556,828	_	556,828
Total operating expenses		2,696,062		2,696,062
Change in net assets from operating activities		(431,945)	(4,500)	(436,445)
Nonoperating activities				
Investment return, net (note 3)		1,744,121	3,514	1,747,635
Change in net assets		1,312,176	(986)	1,311,190
Net assets, beginning of year		14,406,267	127,426	14,533,693
Net assets, end of year	\$	15,718,443	126,440	15,844,883

Alpha Omega Alpha Honor Medical Society Statement of Functional Expenses Year Ended August 31, 2024

-	Programs									Sup	porting service	es	
_	The Pharos	Student awards	Leadership	Chapter development & other	Visiting Professor- ships	Insignia	Distinguished teacher awards	Profession- alism awards	Total program services	Managemen and general		Total supporting services	Total
Salaries, benefits, taxes \$	381,562	94,917	122,167	148,424	25,222	34,068	24,179	68,179	898,718	127,027	_	127,027	1,025,745
Solicitations	_	_	_	_	_	_	_	_	_	_	77,760	77,760	77,760
Merchandise	_	_	_	_	_	194,703	_	_	194,703	_	_	-	194,703
Program support	219,235	327,413	181,835	118,572	84,532	_	59,419	94,366	1,085,372	_	_	_	1,085,372
Occupancy	34,917	8,686	11,180	13,582	2,308	3,118	2,213	6,239	82,243	11,624	_	11,624	93,867
Bank and other fees	_	_	_	_	_	_	_	_	_	150,909	_	150,909	150,909
Office expenses	18,441	4,587	5,904	7,173	1,219	1,647	1,169	3,295	43,435	6,140	_	6,140	49,575
Board expense	_	_	_	-	_	_	_	_	_	62,417	_	62,417	62,417
Technology upgrades	_	_	_	-	_	_	_	_	_	26,345	_	26,345	26,345
Insurance	-	_	_	-	_	_	_	_	_	8,931	_	8,931	8,931
Professional fees		-				_				93,290		93,290	93,290
Total functional expenses \$	654,155	435,603	321,086	287,751	113,281	233,536	86,980	172,079	2,304,471	486,683	77,760	564,443	2,868,914

Alpha Omega Alpha Honor Medical Society Statement of Functional Expenses Year Ended August 31, 2023

-	Programs								Sup	porting servi	ces		
_	The Pharos	Student awards	Leadership	Chapter development & other	Visiting Professor- ships	Insignia	Distinguished teacher awards	Profession- alism awards	Total program services	Managemen and general		Total supporting services	Total
Salaries, benefits, taxes \$	370,031	90,122	125,585	119,187	25,192	25,345	28,567	53,873	837,902	171,134	_	171,134	1,009,036
Solicitations	-	_	_	_	_	_	_	_	_	_	40,556	40,556	40,556
Merchandise	_	_	_	_	_	163,966	_	_	163,966	_		_	163,966
Program support	219,302	297,983	171,762	71,561	106,934	_	61,060	75,493	1,004,095	_		_	1,004,095
Occupancy	33,988	8,278	11,535	10,948	2,314	2,328	2,624	4,948	76,963	15,719	=	15,719	92,682
Bank and other fees	_	_	_	=	=	=	_	=	_	76,328	=	76,328	76,328
Office expenses	24,867	6,056	8,439	8,010	1,693	1,703	1,920	3,620	56,308	11,213	_	11,213	67,521
Board expense	_	_	_	=	=	=	_	=	_	80,128	=	80,128	80,128
Technology upgrades	_	_	_	=	=	=	_	=	_	24,575	=	24,575	24,575
Insurance	_	_	_	_	_	_	_	_	_	6,646	_	6,646	6,646
Professional fees		_				_			_	130,529		130,529	130,529
Total functional expenses \$_	648,188	402,439	317,321	209,706	136,133	193,342	94,171	137,934	2,139,234	516,272	40,556	556,828	2,696,062

Alpha Omega Alpha Honor Medical Society Statements of Cash Flows August 31, 2024 and 2023

Cash flows from operating activities Change in net assets Adjustments to reconcile change in net assets to net cash provided by operating activities Net realized and unrealized gains on investments Receipts of lifetime dues Change in operating assets and liabilities Employee Retention Tax Credit receivables Employee Retention Tax Credit receivables Prepaid expenses and other assets Accounts payable and accrued expenses Fellowships, grants and awards payable Net cash provided (used in) by operating activities Cash flows from investing activities Purchase of investments Purchase of investments Serviced from sale of investments Net cash provided by investing activities Cash and cash equivalents, beginning of year Supplemental noncash information Operating lease right of use asset \$ 3,200,118 1,311,190 1,			2024	2023
Adjustments to reconcile change in net assets to net cash provided by operating activities Net realized and unrealized gains on investments Net realized and unrealized gains on investments Net realized and unrealized gains on investments (3,721,043) (1,762,227) Amortization of lifetime dues (528,528) (521,004) Receipts of lifetime dues Change in operating assets and liabilities Employee Retention Tax Credit receivables Employee Retention Tax Credit receivables Prepaid expenses and other assets 113,977 (192,083) Accounts payable and accrued expenses (49,624) 143,704 Fellowships, grants and awards payable Net cash provided (used in) by operating activities (233,912) (190,203) Cash flows from investing activities Purchase of investments (549,689) (850,193) Proceeds from sale of investments 920,291 886,368 Net cash provided by investing activities 370,602 36,175 Increase (decrease) in cash and cash equivalents 136,690 (154,028) Cash and cash equivalents, beginning of year 710,163 864,191 Cash and cash equivalents, end of year \$ 846,853 710,163 Supplemental noncash information Operating lease right of use asset \$ 184,138	Cash flows from operating activities		_	
to net cash provided by operating activities Net realized and unrealized gains on investments Net realized and unrealized gains on investments (3,721,043) (1,762,227) Amortization of lifetime dues (528,528) (521,004) Receipts of lifetime dues Change in operating assets and liabilities Employee Retention Tax Credit receivables Employee Retention Tax Credit receivables Prepaid expenses and other assets 113,977 (192,083) Accounts payable and accrued expenses (49,624) 143,704 Fellowships, grants and awards payable Fellowships, grants and awards payable Net cash provided (used in) by operating activities Cash flows from investing activities Purchase of investments (549,689) (850,193) Proceeds from sale of investments (549,689) (850,193) Proceeds from sale of investments (549,689) (850,193) Proceeds from sale of investments (549,689) (154,028) Cash and cash equivalents, beginning of year Tio,163 864,191 Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset \$	Change in net assets	\$	3,200,118	1,311,190
Net realized and unrealized gains on investments (3,721,043) (1,762,227) Amortization of lifetime dues (528,528) (521,004) Receipts of lifetime dues 735,903 757,126 Change in operating assets and liabilities — 77,000 Prepaid expenses and other assets 113,977 (192,083) Accounts payable and accrued expenses (49,624) 143,704 Fellowships, grants and awards payable 15,285 (3,909) Net cash provided (used in) by operating activities (233,912) (190,203) Cash flows from investing activities (549,689) (850,193) Purchase of investments (549,689) (850,193) Proceeds from sale of investments 920,291 886,368 Net cash provided by investing activities 370,602 36,175 Increase (decrease) in cash and cash equivalents 136,690 (154,028) Cash and cash equivalents, beginning of year 710,163 864,191 Cash and cash equivalents, end of year \$ 846,853 710,163 Supplemental noncash information — 184,138	Adjustments to reconcile change in net assets			
Amortization of lifetime dues Receipts of lifetime dues Change in operating assets and liabilities Employee Retention Tax Credit receivables Employee Retention Tax Credit receivables Prepaid expenses and other assets Accounts payable and accrued expenses Fellowships, grants and awards payable Net cash provided (used in) by operating activities Cash flows from investing activities Purchase of investments Purchase of investments Net cash provided by investing activities Net cash provided by investing activities Net cash provided by investing activities 136,690 Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset (522,528) (521,004) 735,903 757,126 770,000	to net cash provided by operating activities			
Receipts of lifetime dues Change in operating assets and liabilities Employee Retention Tax Credit receivables Employee Retention Tax Credit receivables Frepaid expenses and other assets Accounts payable and accrued expenses Accounts payable and accrued expenses Accounts payable and awards payable Fellowships, grants and awards payable Net cash provided (used in) by operating activities Cash flows from investing activities Purchase of investments Purchase of investments Net cash provided by investing activities Net cash provided by investing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset 735,903 757,126 770,000 777,000 7192,083 719,203 719,203 719,203 723,912 723,912 723,912 724,928 725,126 726,689 727,126 727,000 728,000	Net realized and unrealized gains on investments		(3,721,043)	(1,762,227)
Change in operating assets and liabilities Employee Retention Tax Credit receivables Frepaid expenses and other assets Accounts payable and accrued expenses Fellowships, grants and awards payable Net cash provided (used in) by operating activities Cash flows from investing activities Purchase of investments Purchase of investments Proceeds from sale of investments Net cash provided by investing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset - 77,000 113,977 (192,083) 143,704 143,704 143,704 15,285 (233,912) (190,203) (850,193) 865,0193 870,602 36,175 136,690 (154,028) 136,690 (154,028) Cash and cash equivalents, beginning of year 710,163 864,191 Cash and cash equivalents, end of year \$846,853 710,163	Amortization of lifetime dues			, ,
Employee Retention Tax Credit receivables Prepaid expenses and other assets Accounts payable and accrued expenses Accounts payable and accrued expenses Fellowships, grants and awards payable Net cash provided (used in) by operating activities Cash flows from investing activities Purchase of investments Purchase of investments Forceeds from sale of investments Net cash provided by investing activities Net cash provided by investing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset - 77,000 (192,083) 113,977 (192,083) 15,285 (3,909) 15,285 (3,909) (190,203) (190,203) (850,193) (850,	Receipts of lifetime dues		735,903	757,126
Prepaid expenses and other assets 113,977 (192,083) Accounts payable and accrued expenses (49,624) 143,704 Fellowships, grants and awards payable 15,285 (3,909) Net cash provided (used in) by operating activities (233,912) (190,203) Cash flows from investing activities (549,689) (850,193) Purchase of investments 920,291 886,368 Net cash provided by investing activities 370,602 36,175 Increase (decrease) in cash and cash equivalents 136,690 (154,028) Cash and cash equivalents, beginning of year 710,163 864,191 Cash and cash equivalents, end of year \$ 846,853 710,163 Supplemental noncash information \$ - 184,138				
Accounts payable and accrued expenses Fellowships, grants and awards payable Net cash provided (used in) by operating activities Cash flows from investing activities Purchase of investments Purchase of investments Proceeds from sale of investments Net cash provided by investing activities 136,690 Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset 143,704 153,704 154,028 15,285 (3,909) 154,0203 (850,193) 1886,368 170,163 170,163 170,163 170,163 170,163 170,163 170,163 170,163 170,163 170,163	e f		_	·
Fellowships, grants and awards payable Net cash provided (used in) by operating activities Cash flows from investing activities Purchase of investments Proceeds from sale of investments Net cash provided by investing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset 15,285 (3,909) (190,203) (190,203) (850,193) (850,	Prepaid expenses and other assets		113,977	(192,083)
Net cash provided (used in) by operating activities Cash flows from investing activities Purchase of investments Proceeds from sale of investments Net cash provided by investing activities Net cash provided by investing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset (233,912) (190,203) (850,193) (850,193) 886,368 370,602 36,175 Increase (decrease) in cash and cash equivalents 136,690 (154,028) Supplemental noncash information Operating lease right of use asset	± •		(49,624)	143,704
Cash flows from investing activities Purchase of investments Proceeds from sale of investments Net cash provided by investing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset (549,689) (850,193) 886,368 370,602 36,175 Increase (decrease) in cash and cash equivalents 136,690 (154,028) 846,853 710,163	Fellowships, grants and awards payable		15,285	(3,909)
Purchase of investments Proceeds from sale of investments Net cash provided by investing activities Increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset (549,689) (850,193) 886,368 370,602 36,175 136,690 (154,028) 864,191 710,163 864,191 Supplemental noncash information Operating lease right of use asset \$	Net cash provided (used in) by operating activities	_	(233,912)	(190,203)
Proceeds from sale of investments Net cash provided by investing activities 1370,602 136,175 Increase (decrease) in cash and cash equivalents 136,690 Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset 920,291 886,368 370,602 36,175 136,690 (154,028) 864,191 Supplemental noncash information Operating lease right of use asset \$	Cash flows from investing activities			
Net cash provided by investing activities 370,602 36,175 Increase (decrease) in cash and cash equivalents 136,690 (154,028) Cash and cash equivalents, beginning of year 710,163 864,191 Cash and cash equivalents, end of year \$846,853 710,163 Supplemental noncash information Operating lease right of use asset \$ 184,138	Purchase of investments		(549,689)	(850,193)
Increase (decrease) in cash and cash equivalents Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset 136,690 (154,028) 864,191 710,163 846,853 710,163	Proceeds from sale of investments		920,291	886,368
Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Supplemental noncash information Operating lease right of use asset Topic 10,163 864,191 846,853 710,163	Net cash provided by investing activities		370,602	36,175
Cash and cash equivalents, end of year \$\\ \\$ \\ \ \ \ \ \ \ \ \ \ \ \ \ \ \	Increase (decrease) in cash and cash equivalents		136,690	(154,028)
Supplemental noncash information Operating lease right of use asset \$	Cash and cash equivalents, beginning of year	_	710,163	864,191
Operating lease right of use asset \$	Cash and cash equivalents, end of year	\$_	846,853	710,163
Operating lease right of use asset \$	Supplemental noncash information			
		\$	_	184,138
Operating reade maching	Operating lease liability	\$ \$	_	183,598

Notes to Financial Statements

August 31, 2024 and 2023

(1) Summary of Significant Accounting Policies

(a) Organization

Alpha Omega Alpha Honor Medical Society ($A\Omega A$) is a nonprofit honor medical society, organized in 1902, and currently has 138 self-directed chapters at medical schools in the United States and Lebanon. $A\Omega A$'s financial statements do not include chapter financial activities.

 $A\Omega A$ publishes *The Pharos*, a quarterly, multidisciplinary, peer-reviewed medical humanities journal, and sponsors thirteen national fellowships, grants, and awards available to all students, residents, faculty, fellows, and community and private physicians. These awards include visiting professorships; distinguished teacher awards; student research fellowships; postgraduate research fellowships; essay and poetry awards; excellence in inclusion, diversity, and equity; and recognition for $A\Omega A$ chapter administrative personnel and volunteer clinical faculty. $A\Omega A$ promotes leadership through its Medical Student Service Leadership Project grant, Fellow in Leadership, and Professionalism awards.

 $A\Omega A$'s revenue is derived primarily from membership dues, return on investments, and contributions.

(b) Basis of Accounting

The accompanying financial statements of A Ω A have been prepared on the accrual basis of accounting, and accordingly reflect all significant receivables, payables, and other liabilities.

(c) Financial Statement Presentation

 $A\Omega A$ is required to present information regarding its financial position and activities according to the following net asset classifications:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of A Ω A. These net assets may be used at the discretion of A Ω A's management and the board of directors.

Net assets with donor restrictions – Net assets subject to stipulations imposed by donors and grantors. Some donor restrictions are temporary in nature; those restrictions will be met by actions of $A\Omega A$ or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity.

(d) Measure of Operations

The statements of activities report all changes in net assets, including changes in net assets from operating and nonoperating activities. Operating activities consist of those items attributed to $A\Omega A$'s ongoing activities and program services. Nonoperating activities are limited to resources that generate return from investments and other activities considered to be of a more unusual or nonrecurring nature.

Notes to Financial Statements, Continued

(1) Summary of Significant Accounting Policies, Continued

(e) Cash and Cash Equivalents

For purposes of the statements of cash flows, A Ω A considers all highly liquid investments with an initial maturity of three months or less, and which are not held by investment managers as part of an investment portfolio, to be cash equivalents.

(f) Concentrations

Financial instruments which potentially subject $A\Omega A$ to concentrations of credit risk consist of investments. Investments are made by investment consultants engaged by $A\Omega A$ and are monitored by the Investment Committee of the Board of Directors and management. Though the market value of investments is subject to fluctuations on a year-to-year basis, management believes the investment policy is prudent for the long-term welfare of $A\Omega A$.

(g) Investments

 $A\Omega A$ reports investments at fair value. Fair value is determined as more fully described in note 1(h). $A\Omega A$'s management is responsible for the fair value measurement of investments reported in the financial statements and believes the reported values are reasonable. Investment return consists of $A\Omega A$'s distributive share of any interest, dividends, and capital gains and losses generated from investments. Investment gain or loss (including realized and unrealized gains and losses on investments) is included in the change in net assets in the statements of activities as increases or decreases in net assets without donor restrictions unless the income or loss is restricted by donor or law.

(h) Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset in the principal or most advantageous market for the asset in an orderly transaction between market participants on the measurement date. Fair value should be based on the assumptions market participants would use when pricing an asset. U.S. generally accepted accounting principles establish a fair value hierarchy that prioritizes investments based on those assumptions. The fair value hierarchy gives the highest priority to quoted prices in active markets (observable inputs) and the lowest priority to an entity's assumptions (unobservable inputs). Assets are grouped in three levels based on the markets in which the assets are traded, and the reliability of the assumptions used to determine fair value. These levels are:

- Level 1 Unadjusted quoted market prices for identical assets or liabilities in active markets as of the measurement date.
- Level 2 Inputs other than quoted market prices observable for the asset/liability, either directly or indirectly.
- Level 3 Unobservable inputs that cannot be corroborated by observable market data.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, an investment's level within the fair value hierarchy is based on the lowest level of input significant to the fair value measurement. These classifications (Level 1, 2, and 3) are intended to reflect the observability of inputs used in the valuation of investments and are not necessarily an indication of risk or liquidity.

Notes to Financial Statements, Continued

(1) Summary of Significant Accounting Policies, Continued

(h) Fair Value Measurements, Continued

In addition, certain investments are reported using the "practical expedient" method. The practical expedient method allows net asset value per share or its equivalent to represent fair value for reporting purposes when the criteria for using this method are met. Investments valued using net asset value per share or its equivalent are not categorized within the hierarchy.

(i) Leases

 $A\Omega A$ has elected not to record in the statements of financial position a lease whose term is twelve months or less and does not include a purchase option that $A\Omega A$ is reasonably certain to exercise. $A\Omega A$ has elected to use the risk-free rate to determine the present value of the lease payments for the purpose of calculating the right of use assets and lease liabilities when the rate implicit to the lease is not readily determinable.

(j) Revenue Recognition

Contributions

Contributions received are recorded as net assets with donor restrictions or net assets without donor restrictions, depending on the existence or nature of any donor restrictions.

All donor-restricted support, including pledges, is reported as an increase in net assets with donor restrictions, depending on the nature of the restriction. When a donor restriction expires, (that is, when a stipulated time restriction ends or purpose restriction is accomplished), net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as net assets released from donor restrictions.

Membership Dues

Management has determined membership dues do not represent a commensurate exchange of value between $A\Omega A$ and the member and are, therefore, contributions. As such, $A\Omega A$'s annual membership dues are recognized as revenue at the time the payment is received. $A\Omega A$ also offers the option of a one-time lifetime membership dues payment. Although lifetime membership dues are also contributions, $A\Omega A$ chooses to record these payments as deferred lifetime dues and amortize them over the estimated membership service period, which is based on the member's estimated age at the time of electing to pay lifetime dues. $A\Omega A$ believes this method presents the most accurate representation of the intended use of these dues payments.

Insignia and Other

Revenue is recognized for insignia and other sales at the time of the sale when the goods are delivered to the buyer.

Notes to Financial Statements, Continued

(1) Summary of Significant Accounting Policies, Continued

(k) Functional Allocation of Expenses

The costs of providing program and supporting services have been summarized on a functional basis in the accompanying statements of functional expenses. A Ω A incurs expenses that directly relate to, and can be assigned to, a specific program or supporting activity. A Ω A also conducts a number of activities which benefit both program objectives as well as supporting services (i.e. management and general and solicitations activities). These costs, which are not specifically attributable to a specific program or supporting activity, are allocated by management on a consistent basis among program and supporting services benefited, based on either financial or nonfinancial data, such as estimates of time and effort incurred by personnel.

(l) Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(m) Income Taxes

 $A\Omega A$ is exempt from federal income tax under Section 501(c)(3) of the Internal Revenue Code. Accordingly, $A\Omega A$ qualifies for the charitable contribution deduction. Income from activities not directly related to $A\Omega A$'s tax-exempt purpose is subject to taxation as unrelated business income. There was no unrelated business income subject to tax in 2024.

Management is required to evaluate tax positions taken by $A\Omega A$ and to recognize a tax liability if $A\Omega A$ has taken an uncertain position that probably would not be sustained upon examination by taxing authorities. $A\Omega A$ believes it has appropriate support for any tax positions taken and none would require recognition of a liability or disclosure in the financial statements. $A\Omega A$ is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. Management believes $A\Omega A$ is no longer subject to income tax examinations for years prior to August 31, 2021.

(n) Subsequent Events

Management has evaluated subsequent events through February 21, 2025, the date the financial statements were available to be issued. No events were identified.

Notes to Financial Statements, Continued

(2) Liquidity and Availability of Financial Assets

The following represents $A\Omega A$'s financial assets available for general expenditures within one year as of August 31:

	<u>2024</u>	<u>2023</u>
Cash and cash equivalents	\$ 846,853	710,163
Operating investments	<u>28,017,283</u>	<u>24,408,405</u>
Financial assets available to meet cash		
expenditures over the next twelve months	\$ <u>28,863,095</u>	<u>25,118,568</u>

 $A\Omega A$'s financial assets available to meet cash needs for general expenditures within one year represent funding for ongoing operational requirements. General expenditures include administrative, program, and solicitation expenses incurred in the conduct of the $A\Omega A$'s ongoing activities. In the normal course of operations, $A\Omega A$ earns revenue from membership fees that are available to meet cash needs for general expenditures throughout the year. As part of its liquidity management, cash in excess of daily requirements is invested in investment funds that provide immediate liquidity.

Investments totaling \$138,240 and \$126,440 at August 31, 2024 and 2023, respectively, represent A Ω A's donor-restricted endowment funds, which are subject to an annual spending policy, and the income from which is restricted for specific purposes as described in note 5.

(3) Investments

Investments are stated at fair value and consist of the following at August 31:

		<u>2024</u>	<u>2023</u>
Cash equivalents and short-term funds	\$	62,633	239,510
Equities Exchange-traded funds Equity mutual funds		1,184,572 5,114,565	735,996 15,747,939
Fixed income Bond mutual funds Diversifiers	11	1,792,712	7,811,400
Hedge fund	_	815,677	1,084,873
	\$ <u>28</u>	<u>8,970,159</u>	<u>25,619,718</u>

 $A\Omega A$ has adopted investment and spending policies approved by the Board of Directors consistent with the Uniform Prudent Management of Institutional Funds Act (UPMIFA) to ensure support for the long-term viability of $A\Omega A$'s programs through consistent, predictable cash flows. The return objective shall be to earn 4.5% on average over longer periods of time (+/- 10 years). $A\Omega A$ has a policy of appropriating for distribution each year 4% of the average value of the endowment assets over the last 12 quarters measured at June 30. $A\Omega A$ employs an outside investment manager to manage its equity and fixed income portfolios, and these funds are largely invested across a highly diversified group of mutual funds.

Notes to Financial Statements, Continued

(3) Investments, Continued

 $A\Omega A$'s net investment return, including interest and dividends on cash and cash equivalents, consists of the following for the years ended August 31:

	<u>2024</u>	<u>2023</u>
Net realized and unrealized gains	\$ 3,721,043	1,762,227
Interest and dividends	69,069	36,679
Less investment fees	(53,116)	(51,271)
Net investment return	\$ <u>3,736,996</u>	1,747,635

The following table summarizes $A\Omega A$'s investments by the fair value hierarchy levels as of August 31, 2024:

		Assets Measured			
	Fair Value	at NAV*	<u>Level 1</u>	<u>Level 2</u>	Level 3
Cash equivalents	\$ 62,633	_	62,633	_	_
Exchange-traded funds	1,184,572	_	1,184,572	_	_
Mutual funds	26,907,277	_	26,907,277	_	_
Hedge fund (a)	<u>815,677</u>	815,677			
Total	\$ 28,970,159	815,677	28,154,482		

The following table summarizes $A\Omega A$'s investments by the fair value hierarchy levels as of August 31, 2023:

			Assets			
		Fair Value	Measured at NAV*	Level 1	Level 2	Level 3
Cash equivalents	\$	239,510	_	239,510	<u> </u>	<u> </u>
Exchange-traded funds		735,996	_	735,996	_	_
Mutual funds		23,559,339	_	23,559,339	_	_
Hedge fund (a)		1,084,873	<u>1,084,873</u>			
Total	5	§ <u>25,619,718</u>	<u>1,084,873</u>	<u>24,534,845</u>		

^{*} Certain investments measured at fair value using the net asset value per share (or its equivalent) practical expedient, which is a reasonable estimate of fair value, have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the statements of financial position.

All assets have been valued using a market approach. There were no changes in the valuation techniques during the current year.

(a) The fair value of the multi-strategy hedge fund was determined using NAV, or its equivalent, and was based on financial information determined and reported by the investment manager. The multi-strategy hedge fund's investment objective is capital appreciation with limited variability of returns, which is achieved by allocating capital among several pooled entities, each managed by an independent investment advisor. Because the hedge fund is a closed-end investment company, the investment is redeemable only semi-annually with 95 days' notice. AΩA has no unfunded commitments to the fund as of August 31, 2024.

Notes to Financial Statements, Continued

(4) Fellowships, Grants, and Awards Payable

At August 31, 2024 and 2023, fellowships, grants, and awards payable total \$403,781 and \$388,496, respectively, and consist of approved but unpaid second- and third-year awards for various $A\Omega A$ programs, including Student Research, Post Graduate, and Medical Student Leadership awards.

(5) Endowment Funds

Net assets with donor restrictions are composed of A Ω A's endowment funds, which consist of the following as of August 31:

	<u>2024</u>	<u>2023</u>
Endowments subject to spending policy and appropriation		
Gifts restricted in perpetuity	\$ 103,715	115,325
Unexpended endowment earnings	33,484	11,115
Total net assets with donor restrictions	\$ <u>137,199</u>	<u>126,440</u>

 $A\Omega A$'s donor-restricted endowment funds restricted in perpetuity consist of the following as of August 31:

	<u>2024</u>	<u>2023</u>
Dr. David J. and Diane L. de Harter Gift Endowment Fund (de Harter Fund)	\$ 70,000	70,000
Robert H. Moser Gift Endowment Fund (Moser Fund)	33,715	45,325
Total donor-restricted endowment funds	\$ <u>103,715</u>	115,325

Net assets associated with these endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

The de Harter Fund endowment gift agreement established \$70,000, with a match of \$30,000 by $A\Omega A$, to be invested in perpetuity. This fund supports $A\Omega A$'s Visiting Professorship program at the University of Wisconsin and is invested according to $A\Omega A$'s investment policy. Up to 4% of the average annual investment return is available for annual distributions. $A\Omega A$ has agreed to match the annual yield of the gift up to 4% of \$100,000 in the $A\Omega A$ investment pool.

The Moser Fund was established to issue a recurring Moser Writing award. The funds are invested under $A\Omega A$'s investment program described in note 3. At August 31, 2024 and 2023, net assets maintained in perpetuity related to the Moser Fund consist of original contributions plus accumulated earnings and appreciation.

 $A\Omega A$ has interpreted UPMIFA as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, $A\Omega A$ classifies as donor-restricted endowment funds to be maintained in perpetuity (a) the original value of gifts donated to the endowment, (b) the original value of subsequent gifts to the endowment, and (c) accumulations to the endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the donor-restricted endowment funds that are not retained in perpetuity are classified as net assets with donor restrictions until those amounts are appropriated for expenditure by $A\Omega A$ management in a manner consistent with the standard of prudence prescribed by UPMIFA.

Notes to Financial Statements, Continued

(5) Endowment Funds, Continued

In accordance with UPMIFA, A Ω A considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- (1) The duration and preservation of the fund
- (2) The purpose of $A\Omega A$ and the donor-restricted endowment fund
- (3) General economic conditions
- (4) The possible effects of inflation and deflation
- (5) The expected total return from income and the appreciation of investments
- (6) Other $\overline{A}\Omega A$ resources
- (7) The investment policies of the $A\Omega A$

Following are the changes in the donor-restricted endowment net assets for 2024 and 2023:

Endowment net assets at August 31, 2022	\$ 127,426
Investment return, net	3,514
Endowment assets appropriated for expenditure	<u>(4,500</u>)
Endowment net assets at August 31, 2023	126,440
Investment return, net	15,259
Endowment assets appropriated for expenditure	<u>(4,500</u>)
Endowment net assets at August 31, 2024	\$ 137,199

Return Objectives and Risk Parameters

The primary investment objective is to generate income and assets to carry out the purpose of the endowment funds while reducing, to the greatest extent possible, the possibility of loss. Consistent with prudent standards of preservation of capital and maintenance of liquidity, the goal is to earn the highest possible total rate of return by investing in socially responsible investment vehicles, consistent with the investment guidelines and social criteria of $A\Omega A$.

Strategies Employed for Achieving Objectives

To satisfy its long-term rate-of-return objectives, $A\Omega A$ relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). To achieve its long-term return objectives within prudent risk constraints, $A\Omega A$ invests across a highly diversified group of mutual funds. $A\Omega A$ has an active investment committee that consistently reviews allocations and returns.

Spending Policy and How the Investment Objectives Relate to Spending Policy

Investment income earned on endowment assets are to be used per donor intent. Distributions from the endowment funds shall not cause the fund's net asset value to drop below the restricted amount. In establishing the spending policy, $A\Omega A$ considers the long-term expected return on its endowments. Accordingly, over the long term, $A\Omega A$ expects the current spending policy to allow its investment portfolio to grow at an average of 4.5% annually. This is consistent with $A\Omega A$'s objective to provide additional real growth through investment return.

Notes to Financial Statements, Continued

(6) Operating Lease Right of Use Asset and Operating Lease Liability

 $A\Omega A$ leases office space under a non-cancelable operating lease that expires in August 2025. $A\Omega A$ includes in the determination of the lease term any renewal options when the options are reasonably certain to be exercised. The operating lease provides for increases in future minimum annual rental payments.

The discount rate is the rate implicit in the lease. For instances where the rate implicit in the lease cannot be readily determined, $A\Omega A$ uses a risk-free discount rate determined using a period comparable to the lease term.

The total operating lease costs for the years ended August 31, 2024 and 2023 totaled \$93,866 and \$90,682, respectively, and are included with occupancy in the statements of functional expenses. The weighted-average term and discount rates for the operating lease outstanding as of August 31 are as follows:

	<u>2024</u>	<u>2023</u>
Weighted-average term (years)	1.00	2.00
Weighted-average discount rate	3.51%	3.51%

As of August 31, 2024, the remaining payments under this lease total \$95,050.

(7) Employee Retirement Plan

The employees of A Ω A participate in a defined contribution plan under Section 403(b) of the Internal Revenue Code. A Ω A is required to contribute 10% of employees' eligible compensation to the plan annually. Pension expense incurred for the years ended August 31, 2024 and 2023 was \$66,825 and \$73,515, respectively.